- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), EBC-129 / A*Star, National Cancer Centre Singapore
Trial completion date, Trial primary completion date, Metastases: EBC-129-01: A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov) - Oct 13, 2023
P1, N=84, Recruiting,
Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Jun 2026
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), EBC-129 / A*Star, National Cancer Centre Singapore
Enrollment open, Metastases: EBC-129-01: A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov) - May 25, 2023
P1, N=84, Recruiting,
Trial completion date: May 2025 --> Jun 2026 | Trial primary completion date: Apr 2025 --> Jun 2026 Not yet recruiting --> Recruiting
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), EBC-129 / A*Star, National Cancer Centre Singapore
Trial primary completion date, Metastases: EBC-129-01: A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov) - Apr 13, 2023
P1, N=84, Not yet recruiting,
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2024 --> Apr 2025
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), EBC-129 / A*Star, National Cancer Centre Singapore
Trial primary completion date, Metastases: EBC-129-01: A Study of EBC-129 in Advanced Solid Tumours (clinicaltrials.gov) - Mar 8, 2023
P1, N=84, Not yet recruiting,
Trial primary completion date: Mar 2024 --> Apr 2025 Trial primary completion date: Mar 2025 --> Mar 2024
|
